Sponsored by the Cardiovascular Research Foundation
Supported through an educational grant from Chiesi USA, Inc.
You must be a SCAI 2019 registrant
to attend these satellite programs.
The decision to use P2Y12 Inhibitors has been the cornerstone treatment of patients with acute coronary syndrome (ACS). Through stimulating case presentations, gain comprehensive understanding of optimal anti-platelet coverage in patients with ACS, patients with complex stable CAD, and the available pharmacotherapy treatments for selected cases. Gain valuable insight into the correct timing and modality of transition from intravenous to oral platelet inhibition in patients. Plus, learn vital tips on guiding the transition to oral P2Y12 receptor blockades from experts in the field.
At the end of this program, the attendees will be able to:
The Cardiovascular Research Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Cardiovascular Research Foundation designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is designed for interventional cardiologists, clinical cardiologists, and other healthcare professionals involved in the management of PCI patients.
Evaluation by questionnaire will address content, presentation effectiveness, possible bias, and future educational needs.
It is the policy of the Cardiovascular Research Foundation to ensure balance, independence, objectivity, and scientific rigor in all of its sponsored educational activities. Commercial support from industry does not influence educational content, faculty selection, and/or faculty presentations, and therefore, does not compromise the scientific integrity of the educational activity.
Discussion of off-label product usage is made at the sole discretion of the faculty. Off-label product discussion and usage is not endorsed by the Cardiovascular Research Foundation, nor the course directors of this activity.
Faculty participating in continuing medical education activities sponsored by the Cardiovascular Research Foundation are required to disclose to the activity audience any real or apparent conflicts of interest related to the content of their presentations. Faculty in noncompliance with this policy are not permitted to participate in this activity.
This program is sponsored by the Cardiovascular Research Foundation and supported through an educational grant from Chiesi USA, Inc. The Cardiovascular Research Foundation ensures that its programs are educational and meet the needs of the target audience. This program was developed without influence from commercial supporters.